Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study — A Randomized Clinical Trial. (vvs.vet)
This is because the recently published EPIC1 study showed that early treatment with pimobendan in MVD Stage B2 dogs will delay the development of symptoms of congestive heart failure (CHF) by an average of 15 months. (vvs.vet)
Dogs in the standard - dose and low - dose pimobendan groups had significantly longer median survival times than dogs in the conventional group (334, 277 and 136 days, respectively; P < 0.001). (jstage.jst.go.jp)